CP
NBIX icon

Cumberland Partners’s Neurocrine Biosciences NBIX Stock Holding History

Cumberland Partners’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-3,000
Closed -$414K – 196
2024
Q1 		$414K Buy
+3,000
New +$410K 0.03% 173

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Cumberland Partners's NBIX Position: Q2 2024 in Review

Cumberland Partners sold out of Neurocrine Biosciences (NBIX) in Q2 2024, closing a stake of 3,000 shares — an estimated $414K sold.

Cumberland Partners first reported a position in NBIX in Q1 2024 and held it in 1 quarter. The position peaked at $414K in Q1 2024. 594 funds tracked by Wall St. Rank hold NBIX as of Q2 2024.

  • Cumberland Partners reported no remaining Neurocrine Biosciences position as of Q2 2024 after selling out during the quarter.
  • Cumberland Partners sold 3,000 Neurocrine Biosciences shares in Q2 2024, an estimated $414K.
  • Cumberland Partners first reported a position in Neurocrine Biosciences in Q1 2024 and held it in 1 quarter.
  • Cumberland Partners's Neurocrine Biosciences position peaked at $414K in Q1 2024.
  • 594 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2024.

Based on Cumberland Partners's 13F filing for Q2 2024, filed 13 Aug 2024.